Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain

Table 2 Guidelines/expert consensus recommendations for ion channel drugs

Ref.	Year	Institution	Recommendations
			Sodium channel blockers	Calcium channel modulators
Finnerup et al[15]	2016	IASP	Topical use of lidocaine for PHN (first-line medication); Carbamazepine and oxcarbazepine for TN (first-line medication)	Gabapentin and pregabalin for NPP (first-line medication)
Attal et al[16]	2010	EFNS	Same with IASP (2010)	Gabapentin and pregabalin for diabetic neuralgia, PHN, central pain (first-line medication); Gabapentin not recommended for HIV neuralgia, post-traumatic neuralgia
CASP neuropathic pain treatment expert group[17]	2013	CASP	Same with IASP (2010); Bulleyaconitine A and lidocaine infusion is effective for NPP; Local anesthetics recommended for nerve block and intrathecal drug infusion	Same with IASP (2010)
Moulin et al[18]	2014	CPS	Topical use of lidocaine (second-line medication)	Same with IASP (2010)
Sumitani et al[19]	2018	JSPC	Carbamazepine for TN (first-line medication); Oxcarbazepine is not approved in Japan	Same with IASP (2010)

CASP: Chinese Association for the Study of Pain; CPS: Canadian Pain Society; EFNS: European Federation of Neurological Societies; HIV: Human immunodeficiency virus; IASP: International Association for the Study of Pain; JSPC: Japanese Society of Pain Clinicians; NPP: Neuropathic pain; PHN: Postherpetic neuralgia; TN: Trigeminal neuralgia.